Good call.
If approved, does Sandoz launch "at risk"?
I would guess yes.
teva will do their best to delay though, file a bunch of CP's, push the fda to require trials, any stunt they can think of.
Good news is there's a second product to value and the analysts that had "everything ex-lovenox" at a dollar or what not will need to rethink.
Market Data 
Markets 
AI
